Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EVT 501
- Development stage
- Preclinical
- Lead developer
- Evotec
- Modality
- Small Molecules
01
Overview
EVT 501 is an investigational small‑molecule histamine H3 receptor antagonist discovered by Evotec and developed within its H3 antagonist program for central nervous system indications such as cognitive and sleep disorders, and excessive fatigue associated with diseases like multiple sclerosis. As an H3 receptor antagonist/inverse agonist, EVT 501 is designed to block presynaptic histamine H3 autoreceptors in the brain, thereby increasing histamine and other neurotransmitter release in key wakefulness and cognition pathways. Evotec advanced EVT 501 into preclinical development with kilogram‑scale active pharmaceutical ingredient manufacturing and regulatory toxicology and safety pharmacology studies, with the intention to partner the program for further clinical development.[1][3][5][9]
Beyond the preview
Go deeper on EVT 501.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EVT 501.